MARVELD1 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
Alpelisib is a selective PI3K inhibitor that targets the PIK3CA gene, leading to the inhibition of the PI3K/AKT/mTOR pathway. This pathway can regulate MARVELD1 expression, so inhibiting it could decrease MARVELD1 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. By blocking EGFR, it indirectly affects downstream signaling pathways involved in the regulation of MARVELD1, potentially decreasing its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which interferes with the mTOR signaling pathway. Since MARVELD1 expression can be influenced by this pathway, rapamycin may reduce MARVELD1 activity by inhibiting mTOR. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is upstream of AKT and mTOR. It would decrease MARVELD1 activity by inhibiting the PI3K/AKT/mTOR signaling axis that can regulate MARVELD1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which interferes with the MAPK/ERK pathway. The MAPK/ERK pathway can modulate MARVELD1, and inhibition by PD98059 could lead to reduced MARVELD1 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor affecting the MAPK/ERK pathway. It could indirectly lower MARVELD1 activity by inhibiting this pathway, which is potentially involved in MARVELD1 regulation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor like gefitinib and can decrease MARVELD1 activity by inhibiting downstream signaling pathways that may regulate MARVELD1. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is a derivative of rapamycin and acts as an mTOR inhibitor. It would inhibit MARVELD1 activity by suppressing the mTOR signaling pathway, which could influence MARVELD1 regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, which could impact several pathways including those that may regulate MARVELD1, leading to its decreased activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that targets the MAPK/ERK pathway. Inhibition of this pathway could lead to decreased MARVELD1 activity if MARVELD1 is regulated by this pathway. | ||||||